Biocytogen Lists on STAR Market, Opening Price Surges 117% to 58 RMB
Written by Emily J. Thompson, Senior Investment Analyst
Source: Businesswire
Updated: 1 hour ago0mins
- Listing Milestone: Biocytogen successfully lists on the STAR Market with an IPO price of 26.68 RMB, opening at 58 RMB, a 117% increase, resulting in a market cap exceeding 25.9 billion RMB, marking its position as the first “H+A” dual-listed global drug innovator.
- Platform Advantage: The company’s RenMice® platforms enable the discovery of fully human monoclonal antibodies across over 1,000 druggable targets, having advanced more than 40 PCC-to-IND stage assets, showcasing its robust capabilities in antibody drug development.
- Global Collaborations: Biocytogen has established over 280 global discovery partnerships and successfully out-licensed more than 10 clinical or near-clinical programs, further solidifying its leadership in the global biotechnology sector.
- Strategic Expansion: This listing will facilitate Biocytogen's global expansion and platform commercialization, leveraging the synergies of its “H+A” dual-listing structure to deepen collaborations with international partners and drive the discovery of novel therapies to benefit global healthcare.
02315.HK
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on 02315
Wall Street analysts forecast 02315 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02315 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 33.000
Low
Averages
High
Current: 33.000
Low
Averages
High
No Data
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?